James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cel...
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which c...
Roy S. Herbst, MD, PhD, of the Yale School of Medicine, summarizes a session that included discussion of the mechanisms of immunotherapies, biomarkers for activity of these agents,...
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...
